CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 45 enrolled
Drug / intervention
MK-8776 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00779584
NCT00779584Phase 1Completed
CompareCT.gov

A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma

Merck Sharp & Dohme LLC·interventional·Posted Oct 24, 2008·Updated Aug 27, 2018

In Brief

A Phase 1 clinical trial evaluating MK-8776 and Gemcitabine for Hodgkin Disease and 2 related conditions. Completed, enrolled 45 participants.

Detailed Summary

This study of MK-8776 (SCH 900776) will evaluate its safety and tolerability when given as monotherapy or in combination with gemcitabine to participants with advanced solid tumors or lymphoma. Participants will be enrolled in cohorts that will receive sequentially higher doses of MK-8776 in combination with standard doses of gemcitabine The recommended combination doses for a Phase 2 trial (combination-RP2D) will be determined based on safety and biological activity. Up to 10 to 15 additional participants may be studied at the combination-RP2D.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 24, 2008
Enrollment StartOct 17, 2008
Primary CompletionMay 28, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 17.7 years ago

Interventions

MK-8776drug

IV infusion

Gemcitabinedrug

IV infusion